OLMA vs. GHRS, STOK, CALT, ZYME, PHAR, LYEL, ORIC, PHAT, SLN, and CVAC
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include GH Research (GHRS), Stoke Therapeutics (STOK), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Pharming Group (PHAR), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Silence Therapeutics (SLN), and CureVac (CVAC). These companies are all part of the "pharmaceutical preparations" industry.
GH Research (NASDAQ:GHRS) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.
GH Research has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500.
Olema Pharmaceuticals' return on equity of -14.56% beat GH Research's return on equity.
Olema Pharmaceuticals received 5 more outperform votes than GH Research when rated by MarketBeat users. However, 67.86% of users gave GH Research an outperform vote while only 61.54% of users gave Olema Pharmaceuticals an outperform vote.
In the previous week, Olema Pharmaceuticals had 20 more articles in the media than GH Research. MarketBeat recorded 28 mentions for Olema Pharmaceuticals and 8 mentions for GH Research. GH Research's average media sentiment score of 0.68 beat Olema Pharmaceuticals' score of 0.54 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.
GH Research is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
56.9% of GH Research shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 23.5% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
GH Research currently has a consensus price target of $36.67, suggesting a potential upside of 187.81%. Olema Pharmaceuticals has a consensus price target of $22.00, suggesting a potential upside of 123.35%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe GH Research is more favorable than Olema Pharmaceuticals.
Summary
Olema Pharmaceuticals beats GH Research on 8 of the 14 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
